Tadalafil Tablet
Product Images NDC 71610-903

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71610-903). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0903 04)

FDA Label Image

Aphena (Aphena)

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

This is an evaluation chart displaying the standing and supine diastolic blood pressure, as well as the standing and supine systolic blood pressure over time in hours. The text also mentions a note about the blood pressure measurements.*

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

This text contains information about a blood pressure study involving tadalafil (20 mg) and doxazosin (8 mg). The graph appears to show the standing systolic blood pressure change over a certain period, which could potentially illustrate the effects of the medications on blood pressure levels.*

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

The text provides information about a study involving the administration of different doses of tadalafil and doxazosin at different times to evaluate their effects on systolic blood pressure. The study compares the impact of 20 mg tadalafil with 8 mg doxazosin in the morning, 20 mg tadalafil with 8 mg doxazosin in the evening, and a control group receiving a placebo with 8 mg doxazosin. The data seems to be related to monitoring systolic blood pressure changes following the administration of these medications at different times.*

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

This text provides information about the change in IPSS Total Score between Tadalafil tablets 5 mg and a placebo over a duration of treatment in weeks. The data indicates a statistically significant difference (p<0.01) between the two treatments.*

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

This text appears to be part of a data set related to a study or clinical trial involving Tadalafil tablets at a dosage of 5 mg. It includes information on the duration of treatment in weeks along with a reference to a placebo group. The data also features a statistical analysis result indicating significance with a p-value of less than 0.001.*

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

This text provides information on the LS Mean Change from Baseline for TadalafilFinasteride and PlaceboFinasteride, along with the Least Squares Treatment Difference. It may be part of a report or clinical study analysis comparing the effects of these treatments.*

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

This text provides information on a study comparing Tadalafil tablets with a placebo over a period of weeks. The significance level is indicated as p<0.01. The data seems to show the impact of treatment duration on the effect of the tablets.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.